News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
Gilead (GILD) Announces SVR12 Rates From Phase III Study Evaluating Harvoni For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV 2/27/2015
Argos Therapeutics, Inc. (ARGS) Announces Update On Phase 3 ADAPT Trial To Be Presented During 2015 ASCO Genitourinary Cancers Symposium 2/27/2015
Gilead (GILD)'s Harvoni Achieves 96% Cure Rate in Patients With Hepatitis C and HIV 2/27/2015
Amgen (AMGN) Receives Positive CHMP Opinion For Use Of Vectibix (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer 2/27/2015
Biogen Idec (BIIB) And Swedish Orphan Biovitrum Announce Positive Top-Line Efficacy And Safety Results From Phase 3 ALPROLIX Pediatric Study 2/27/2015
Gilead (GILD) Announces Phase 3 Results For Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) 2/27/2015
Bristol-Myers Squibb (BMY) Release: ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected With HIV After Ribavirin-Free Investigational 12-Week Regimen Of Daclatasvir And Sofosbuvir 2/27/2015
Amgen (AMGN)'s Hormone-Imbalance Drug AMG 416 Shows Positive Results in Phase 3 Study 2/26/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Chimerix (CMRX) Provides Update On Anticipated SUPPRESS Enrollment 2/26/2015
Portola Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation For Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibitor Antidote 2/26/2015
Gradalis Inc. Announces Initiation Of A Phase 3 Registration Study For Vigil In Ovarian Cancer 2/26/2015
Bristol-Myers Squibb (BMY) Release: Study Of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results In Preventing Viral Replication Via Different Mechanism Of Action Than Current Therapies 2/26/2015
Amgen (AMGN) Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis 2/26/2015
Eisai Inc. (ESALF.PK) Release: Topline Results Of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint Of Overall Survival In Advanced Soft Tissue Sarcoma 2/25/2015
Dipexium Pharmaceuticals (DPRX) Passes 25% Enrollment In Locilex Pivotal Phase 3 Clinical Trials 2/25/2015
Nektar Therapeutics (CA) (NKTR) Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain 2/25/2015
Sunovion Pharmaceuticals Inc. Announces Initiation Of Phase 3 Clinical Trial Program For SUN-101/Eflow (Glycopyrrolate) In Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 2/25/2015
Bristol-Myers Squibb (BMY) Release: 48-Week Analysis Of Investigational HIV-1 Attachment Inhibitor Paves Way For Phase III Trial Initiation 2/25/2015
Antares Pharma, Inc. (ATRS) Announces Positive Top-Line Pharmacokinetic Results From The Quickshot Phase 3 Study In Testosterone Deficient Men 2/25/2015
Cytori Therapeutics, Inc. (CYTX) Receives Positive European Opinion On Orphan Drug Status 2/24/2015
Theravance Biopharma Enrolls First Patient In Phase 3 Registrational Study Of Telavancin In Staphylococcus Aureus Bacteremia 2/24/2015
Teva Pharmaceutical Industries (TEVA) Release: The Lancet Respiratory Medicine And AAAAI Publish Positive Data From Phase 3 Trials Of Teva’s Reslizumab For The Treatment Of Moderate To Severe Asthma In Patients With Elevated Blood Eosinophils 2/24/2015
Celsion Corporation (CLSN) Announces Updated Overall Survival Data from HEAT Study of ThermoDox In Primary Liver Cancer 2/23/2015
TiGenix's Phase III Trial Design For Cx601 Endorsed By President-Elect Of ECCO 2/23/2015
ADMA Biologics, Inc. Announces Positive Data On Primary And Secondary Endpoints From Its Pivotal Phase III Clinical Trial For RI-002 At The American Academy of Allergy, Asthma and Immunology (AAAAI) Medical Conference 2/23/2015
Hemispherx Biopharma (HEB): Institute Of Medicine, The Health Arm Of The US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) As A "Systemic Exertion Intolerance Disease" (SEID) 2/23/2015
Eli Lilly (LLY) Release: Baricitinib Superior To Placebo In Reducing Rheumatoid Arthritis Disease Activity In Second Phase 3 Study 2/23/2015
Results from AbbVie (ABBV)'s Study Of VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) Published Online In JAMA; Sub-Analyses To Be Presented At The Annual Conference On Retroviruses And Opportunistic Infections (CROI) 2/23/2015
Pierre Fabre Release: A phase 2/3 Clinical Data Published In The NEJM Confirms Positive Safety-Efficacy Profile For First Pediatric Treatment For Infantile Hemangioma 2/20/2015
BioTie Therapies Corp. Provides Portfolio Update On Tozadenant 2/20/2015
Immunomedics, Inc. (IMMU) Presents Updated Results With Sacituzumab Govitecan in Lung Cancer 2/20/2015
Actavis (ACT) Touts Potential $6 Billion Pipeline at Investor Meeting 2/19/2015
EXCLUSIVE: Chimerix (CMRX) Says 2015 Will Be "Pivotal" Year, In Talks With Regulators to Use Antiviral After Transplants 2/19/2015
Takeda (TKPYY) Lung Cancer Drug Motesanib Flunks Late Stage Trial 2/19/2015
Nuo Therapeutics Initiates Phase 4 Study Of Aurix Under CMS Coverage With Evidence Development Program 2/19/2015
Eli Lilly (LLY) Provides Update On Evacetrapib Phase 3 Trial 2/19/2015
CEL-SCI (CVM)’s Phase III Head And Neck Cancer Trial Cleared To Begin Patient Enrollment In Malaysia, The 20th Country To Join The Trial 2/19/2015
Sanofi (SAN.PA)'s Cerdelga Shows Promise in Late Stage Trial 2/18/2015
Genzyme (GENZ) Release: ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (Eliglustat) For Treatment-Naïve Patients With Gaucher Disease Type 1 Published In JAMA 2/18/2015
Elite Pharmaceuticals, Inc. (ELI) Provides Guidance On Phase III Study For ELI-200 2/18/2015
PAREXEL International (PRXL) Simplifies Patient Recruitment And Study Start-Up Timelines Through Innovative Site Alliance Network 2/18/2015
Seattle Genetics, Inc. (SGEN) Submits Supplemental BLA To FDA For Phase 3 AETHERA Trial Of ADCETRIS® (Brentuximab Vedotin) In Post-Transplant Hodgkin Lymphoma Patients At High Risk Of Relapse 2/18/2015
Takeda (TKPYY) Announces Phase 3 MONET-A Study Evaluating Motesanib (AMG 706) In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Does Not Meet Primary Endpoin 2/17/2015
Hyperion Therapeutics (HPTX) Enters Into Completion Of Phase III Clinical Trial, Option And Mutual Release Agreement With Clal Biotechnology Industries And Yeda Research and Development Company Ltd. 2/17/2015
MediVector Completes Patient Enrollment In Two Phase 3 Studies Of Favipiravir For Influenza 2/17/2015
Navidea Biopharmaceuticals (NAVB) Release: Lymphoseek Results From Phase 3 Clinical Trial In Oral Cavity Cancer Of The Head And Neck Published In Annals Of Surgical Oncology 2/17/2015
Improved Survival In Children With Graft Versus Host Disease Who Respond To Mesoblast Limited (MSB.AX)'s Cell Therapy 2/16/2015
Eisai Inc. (ESALF.PK) Release: Pivotal Phase 3 Trial of Investigational Agent Lenvatinib In Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published In New England Journal Of Medicine 2/12/2015
Chimerix, Inc. (CMRX) Presents Update On Preliminary Data From Advise Study Of Brincidofovir For Adenovirus Infection At BMT Tandem Meetings 2/12/2015
Genzyme (GENZ) Presents Phase 3 Clinical Trial Extension Results For Cerdelga® (Eliglustat) At Lysosomal Disease Network’s WORLD Symposium 2015 2/12/2015
BIOCEO15: Gilead (GILD) COO Says 6-Week Timeline for Hep C Course Unrealistic, Outlines NASH, Cancer Strategies 2/12/2015
The Philippines Is The 19th Country To Clear CEL-SCI (CVM) For Patient Enrollment In Its Phase III Head And Neck Cancer Trial 2/11/2015
Baxter International, Inc. (BAX) Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-Life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A 2/11/2015
Interim Phase 3 Results Positive for Takeda (TKPYY) Blood Cancer Med Ixazomib 2/10/2015
Anthera Pharmaceuticals, Inc. (ANTH) Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For Systemic Lupus Erythematosus 2/10/2015
Amicus Therapeutics, Inc. (FOLD) Announces Additional Positive Phase 3 Fabry Data On Patient Reported Outcomes At Worldsymposium 2015 2/10/2015
AB Science (AB.PA) : Successful Completion Of Futility Test For Masitinib In Alzheimer's Disease 2/10/2015
Galena Biopharma  (GALE) Enrolls 700th Patient In Neuvax (Nelipepimut-S) Phase 3 PRESENT Clinical Trial 2/9/2015
La Jolla Pharmaceutical Company (LJPC) Announces Special Protocol Assessment For Planned Phase 3 Trial Of LJPC-501 In Catecholamine-Resistant Hypotension 2/9/2015
Provectus Biopharmaceuticals Inc. Met With FDA On Operational Aspects Of PV-10 Phase 3 Melanoma Study 2/9/2015
Chiasma Inc. Release: Newly Published Phase 3 Study Results Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder 2/9/2015
GlaxoSmithKline (GSK) And Theravance, Inc. (THRX) Announce Start Of Phase 3 Lung Function Study With 'Closed' Triple Combination Treatment FF/UMEC/VI For COPD 2/9/2015
Newly Presented Data Shows That Peregrine Pharmaceuticals, Inc. (PPHM)' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity Of Immune Checkpoint Inhibitors PD-1 And CTLA-4 In Models Of Breast Cancer And Melanoma 2/9/2015
Second Breakthrough Status Win for Genentech (RHHBY) Immunotherapy Drug 2/6/2015
GlaxoSmithKline (GSK) Touts Positive Data From Phase III COMBI-D Study 2/6/2015
Portola Pharmaceuticals, Inc.'s Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis In Phase 3 APEX Study; Trial Continues As Planned And Remains On Track For Enrollment Completion By Year-End 2/6/2015
Cognoptix CEO Paul Hartung Says Company Is Preparing For A Pivotal Phase 3 Clinical Trial Of SAPPHIRE Eye Scan Being Developed To Aid In The Early Detection Of Alzheimer’s Disease 2/5/2015
Genentech (RHHBY) Shows Off Positive Phase III Lymphoma Data From Late-Stage Study 2/5/2015
Amgen (AMGN) Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate Abp 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis 2/4/2015
Daiichi Sankyo, Inc. (4568.t) Announces First Patients In Large-Scale, Multi-National Phase 3 Clinical Programs For Mirogabalin 2/4/2015
Can-Fite BioPharma (CFBI) Completes Phase 2/3 Trial For CF101 In Treatment of Psoriasis 2/4/2015
Roche (RHHBY)’s Phase 3 Study Of Gazyva/Gazyvaro Showed Significant Benefit In Refractory Indolent Non-Hodgkin’s Lymphoma 2/4/2015
Genentech (RHHBY)’s Phase III Study Of Gazyva Showed Significant Benefit In Refractory Indolent Non-Hodgkin’s Lymphoma 2/4/2015
EXCLUSIVE: Esperion Therapeutics, Inc. (ESPR) CEO Says FDA Lift Means ETC-1002 Will Be in Phase III Trials By End of 2015 2/4/2015
Flexion Therapeutics (FLXN) Initiates Phase 3 Clinical Trial Of FX006 In Patients With Osteoarthritis Of The Knee 2/3/2015
CTI BioPharma Announces Independent DMC Recommendation To Continue GOG-0212 Phase 3 Study Of OPAXIO™ As Maintenance Therapy In Ovarian Cancer, An NRG Oncology/GOG Study 2/3/2015
Onconova Therapeutics Inc. (ONTX) Announces Clinical Development Plan For Rigosertib In Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure Of Treatment With Hypomethylating Agents (Hmas) 2/3/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 2/3/2015
Chimerix, Inc. (CMRX) Focusing Efforts On CMV And Adenovirus Pivotal Trials 2/2/2015
Emmaus Life Sciences Phase 3 Sickle Cell Disease Trial Data Included In 2015 Highlights Of American Society of Hematology Program 2/2/2015
CEL-SCI (CVM) Reports Record Monthly Patient Enrollment In Its Phase III Head And Neck Cancer Trial 2/2/2015
Enanta Pharmaceuticals, Inc. Announces 95 Percent SVR12 Rate In Abbvie’s Phase 3 Study Of All-Oral Treatment For Hepatitis C Virus In Japanese Patients 2/2/2015
FDA Grants Breakthrough Therapy Designation For Genentech (RHHBY)’s Investigational Cancer Immunotherapy MPDL3280A (Anti-PDL1) In Non-Small Cell Lung Cancer 2/2/2015
AbbVie (ABBV) Announces Top-Line Results From Phase 3 Study Of All-Oral Treatment For Hepatitis C In Japan 2/2/2015
Evoke Pharma, Inc. Outlines Progress On Clinical Program 2/2/2015
Intercept Pharmaceuticals (ICPT) Rockets as Lead NASH Drug Snags Breakthrough Status From the FDA 2/2/2015
Vital Therapies, Inc. (VTI) (VTL) Announces VTI-208 Phase 3 Clinical Trial Reaches Enrollment Target 1/30/2015
Intercept Pharmaceuticals (ICPT) Receives Breakthrough Therapy Designation From FDA For Obeticholic Acid For Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis 1/30/2015
Radius (RDUS) Announces Oral Presentation Of The ACTIVE Phase 3 Clinical Trial Of Abaloparatide-SC For Postmenopausal Women With Osteoporosis At The International Society Of Endocrinology And The Endocrine Society (ICE/ENDO 2015) 1/29/2015
Synergy Pharmaceuticals Completes Patient Enrollment For The Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 1/29/2015
Incyte Corporation (INCY) Announces Publication Of Phase 3 RESPONSE Trial In Patients With Polycythemia Vera In New England Journal Of Medicine 1/29/2015
RedHill Biopharma Ltd. (RDHL) Provides Update On Progress With RHB-104 Ongoing Phase 3 Program For Crohn's Disease Following FDA Meeting 1/29/2015
Protein Sciences Corporation Release: Clinical Efficacy Study Of Flublok® Quadrivalent Compares Flublok To A Traditional Egg-Based Flu Vaccine 1/29/2015
OSE Pharma Collaboration For Cancer Trial 1/29/2015
Alzheimer's Drug Discovery Foundation Release: New Approach To Delay Alzheimer's Dementia Onset To Be Tested In Phase 3 Clinical Trial 1/28/2015
Avita Medical Announces First Patient Enrollment In US Pivotal Study Of Recell® For The Treatment Of Burns 1/28/2015
Taxus Cardium (CRXM) Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 1/27/2015
Shire (SHPGY)'s Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation For The Treatment Of Neurocognitive Decline Associated With Hunter Syndrome 1/26/2015
CEL-SCI (CVM) Receives Regulatory Clearance To Expand Its Phase 3 Head And Neck Cancer Trial Into Romania 1/26/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 1/26/2015
Regeneron (REGN) Release: EYLEA® (aflibercept) Injection Recommended For Approval For The Treatment Of Visual Impairment Due To Macular Edema Secondary To Central Or Branch Retinal Vein Occlusion In The European Union 1/23/2015
ALPHAEON Begins Phase 3 Study For Its Neurotoxin, EVOSYAL 1/22/2015
Shire plc Release: Positive Response From European Decentralised Procedure For Elvanse Adult® (lisdexamfetamine dimesylate) In Adults With ADHD 1/22/2015
FDA Removes Partial Clinical Hold on CytRx Corporation (CYTR)'s Brain Cancer Trials 1/21/2015
The New Billion Dollar Tekmira (TKMR) Includes Promising Hep B Drug 1/20/2015
Celator Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CPX-351 For The Treatment Of Elderly Patients With Secondary Acute Myeloid Leukemia 1/20/2015
Merrimack Pharmaceuticals Inc. (MACK) Presents Additional Analyses Of Phase 3 MM-398 NAPOLI-1 Study At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/20/2015
Actavis (ACT), Gedeon Richter Ltd. (RIG2.F) Say Key Drug Cariprazine Effective on Schizophrenia Relapse 1/20/2015
Choroideremia Research Foundation Release: Groundbreaking Gene Therapy Trial Begins In Philadelphia 1/20/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
Clinical Study Results Presented At The 2015 Gastrointestinal Cancer Symposium Support Utility Of Trovagene's Precision Cancer Monitoring Platform In Colorectal And Pancreatic Cancer Patients 1/20/2015
Marathon Pharmaceuticals, LLC Receives FDA Fast Track Designation For Deflazacort As A Potential Treatment For Duchenne Muscular Dystrophy 1/19/2015
PharmaEngine, Inc. Announces Expanded Analyses Of Phase 3 MM-398 NAPOLI-1 Study Presented At The 2015 American Society of Clinical Oncology GI Substantiate The Positive Results Of MM-398 In Combination With 5-FU/LV 1/19/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer 1/16/2015
J.P. Morgan: AstraZeneca PLC (AZN) CEO Says He's Not Worried About Pricing Pressure 1/15/2015
Janssen Pharmaceutical Inc. Release: Real-World Data Published In Clinical Cardiology Show Consistent Safety Performance Of Once-Daily XARELTO® 1/14/2015
Frost & Sullivan Releases Drug Launch And Phase 3 Trial Watch List For Top Therapeutic Areas 1/13/2015
Pharmamar Will Start A Phase 3 Study Of PM1183 In Combination With Doxorubicin In Relapsed SCLC 1/13/2015
Antares Pharma, Inc. (ATRS) Announces Update To QuickShot® Testosterone Program 1/13/2015
INSYS Therapeutics To Initiate Five Phase 3 Clinical Trials In 2015 1/13/2015
AB Science (AB.PA): The Data and Safety Monitoring Board Recommends The Continuation Of Phase 3 Study Of Masitinib In Amyotrophic Lateral Sclerosis 1/13/2015
Breaking: J.P. Morgan: BioMarin (BMRN) Takes Shot at Sarepta (SRPT), Says DMD Drug Has Better Results So Far 1/13/2015
J.P. Morgan: Celgene (CELG) to Fast-Track Crohn's Drug, Provides Estimates Up to 2020 1/13/2015
Bristol-Myers Squibb Company (BMY) Study Halted After Opdivo Meets Efficacy Endpoint 1/13/2015
Regeneron (REGN), Sanofi (SAN.PA) Show Off Positive Cholesterol Drug Data 1/12/2015
Radius (RDUS) Announces Follow-Up On The Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis 1/12/2015
Portola Pharmaceuticals, Inc. Initiates Phase 4 Study To Support Accelerated Approval Of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote 1/12/2015
Tesaro, Inc. (TSRO) Announces Expansion Of Niraparib Clinical Program And Outlines Late-Stage Program Milestones For 2015 1/12/2015
The Lancet Oncology Publishes Phase 3 Data Showing Gilotrif® (Afatinib) Extends Overall Survival In Lung Cancer Patients Whose Tumors Have The Most Common EGFR Mutation Compared With Chemotherapy 1/12/2015
Aerie Pharmaceuticals, Inc. (AERI) Announces Acceleration Of Expected Timeline For Reporting Efficacy Results From Phase 3 Registration Trial (“Rocket 1”) Of Rhopressa™ 1/12/2015
The Lancet Oncology Publishes Phase III Data Showing Giotrif® (Afatinib*) Significantly Extended Overall Survival Of Lung Cancer Patients With The Most Common EGFR Mutation Over Chemotherapy 1/12/2015
Bristol-Myers Squibb Company (BMY) Release: CheckMate -017, A Phase 3 Study Of Opdivo (Nivolumab) Compared To Docetaxel In Patients With Second-Line Squamous Cell Non-Small Cell Lung Cancer, Stopped Early 1/12/2015
Ligand Pharmaceuticals Inc. (LGND) Partner Retrophin (RTRX) Receives Orphan Drug Designation For Sparsentan 1/9/2015
Shield Therapeutics Announces The Publication Of The AEGIS Feraccru Phase 3 Pivotal Trial Manuscript In The Inflammatory Bowel Disease Journal 1/9/2015
GW Pharmaceuticals (GWPH) Falls as Cannabis Drug Fails Key Cancer Pain Study 1/9/2015
Regeneron (REGN) And Sanofi (SAN.PA) Announce Positive Topline Results From First Phase 3 Trials Evaluating Monthly Dosing Of Alirocumab In Patients With Hypercholesterolemia 1/9/2015
Portola Pharmaceuticals, Inc. Announces Phase 3 ANNEXA-R Study Of Andexanet Alfa And Factor Xa Inhibitor XARELTO® (Rivaroxaban) Met Primary Endpoint With High Statistical Significance 1/9/2015
AbbVie (ABBV), Neurocrine Biosciences, Inc. (NBIX) Drug Successful in Late Stage Endometriosis Trial 1/8/2015
Synergy Pharmaceuticals Completes Patient Enrollment For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 1/8/2015
Novartis AG (NVS) Announces Robust Phase 3 Results For QVA149 And NVA237 And Submits Regulatory Applications To U.S. FDA 1/8/2015
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.)'s Lead Candidate Delafloxacin Yields Positive Top-Line Results In Phase 3 Study In Patients With ABSSSI 1/8/2015
Dermira And UCB SA Announce Start Of Phase 3 Program For CIMZIA® (Certolizumab Pegol) In Psoriasis 1/8/2015
Versartis, Inc. (VSAR) Initiates Global Phase 3 Study Of VRS-317 In Children With Growth Hormone Deficiency 1/8/2015
Chimerix, Inc. (CMRX) Provides Update On Brincidofovir Pivotal Phase 3 Advise Trial For The Treatment Of Adenovirus 1/8/2015
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac Endpoints From Fabry Monotherapy Study 011 And Long Term Extension Study 1/8/2015
Merrimack Pharmaceuticals Inc. (MACK) Announces Oral Presentation Of Additional Analyses Of MM-398 Phase 3 NAPOLI-1 Study At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/8/2015
GW Pharmaceuticals (GWPH) And Otsuka Pharmaceutical Co., Ltd. Announce Results In First Of Three Sativex® Phase 3 Cancer Pain Trials 1/8/2015
FDA Grants Soligenix (SNGX) "Fast Track" Designation For SGX301 For The First-Line Treatment Of Cutaneous T-Cell Lymphoma 1/7/2015
ContraVir Pharmaceuticals Granted FDA Meeting To Discuss Proposal For Phase 3 Trial Of FV-100 1/7/2015
Mirati Therapeutics  (MRTX) Doses First Patient In Investigator-Sponsored Phase 2 Study Of Mocetinostat In Non-Hodgkin's Lymphoma 1/6/2015
TONIX Pharmaceuticals, Inc. (TNXP) Provides Clinical And Regulatory Update On Its Continued Development Of TNX-102 SL In Fibromyalgia 1/6/2015
Alkermes plc (ALKS) Announces Positive Results From Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 1/6/2015
Versartis, Inc. (VSAR) Announces Positive 12 Month Data For VRS-317 from Ongoing Extension Study 1/5/2015
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy In Previously Untreated And Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients 1/5/2015
Cerus Corporation (CERS) Reports EU Phase 3 Clinical Trial Of INTERCEPT Red Blood Cells Met Primary Endpoint 1/5/2015
CEL-SCI (CVM)’s 2014 Patient Enrollment Increases Eight-Fold Over 2013 In Its Phase 3 Head And Neck Cancer Trial 1/5/2015
Cempra Pharmaceuticals, Inc. (CEMP) Surges as Lead Oral Antibiotic Meets Main Goal in Phase 3 Study 1/5/2015
Intersect ENT Announces Enrollment Of First Patient In Phase 3 Study Of In-Office Treatment For Recurrent Chronic Sinusitis 12/30/2014
Can-Fite BioPharma (CFBI) Completes The Design Of The Rheumatoid Arthritis Phase 3 Study Of Its Lead Drug Candidate Cf101 12/30/2014
Palatin Technologies (PTN) Announces Start Of Bremelanotide Phase 3 Program For Female Sexual Dysfunction 12/29/2014
RegeneRx Biopharmaceuticals, Inc. (RGRX) Partner Submits Phase 2B/3 IND To Korean Health Authority For RGN-259 For The Treatment Of Dry Eye Syndrome 12/29/2014
Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells (STEM), Cellular Dynamics 12/24/2014
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/23/2014
Provectus Biopharmaceuticals Inc. To Meet With FDA On Operational Aspects Of PV-10 Phase 3 Melanoma Study With Aim To Maximize Speed Of Enrollment 12/22/2014
Creative Bioarray Introduces Mini-Centrifuges With Outstanding Performance 12/22/2014
Radius (RDUS) Announces Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis 12/22/2014
TiGenix Submits Its Pivotal US Trial Design For Cx601 To The FDA For Special Protocol Assessment 12/22/2014
Receptos (RCPT) Initiates SUNBEAM Phase 3 Trial Of RPC1063 In Relapsing Multiple Sclerosis 12/22/2014
TetraPhase Pharmaceuticals (TTPH) Surges As Antibiotic Succeeds In Late-Stage Trial 12/19/2014
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine Hits Goal In Late-Stage Study 12/19/2014
Pfizer (PFE) Shows Off Significant Data From Pregabalin CR Phase 3 12/19/2014
Roche (RHHBY) Provides Update On Gantenerumab Development Programme 12/19/2014
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation In The United States And The European Union For The Treatment Of Malignant Pleural Mesothelioma 12/19/2014
Cardio3 BioSciences Announces The Enrolment Of The 240th Patient For Its CHART-1 Phase 3 Clinical Trial For The Treatment Of Heart Failure 12/19/2014
ImmunoGen, Inc. (IMGN) Reports Roche (RHHBY) Has Provided An Update On The MARIANNE Trial 12/19/2014
SoCal's Auspex Pharmaceuticals (ASPX) Soars 90% On Huntington's Disease Drug Trial Data 12/18/2014
Pivotal Phase 3 Study Of GlaxoSmithKline (GSK) Shingles Candidate Vaccine Meets Its Primary Endpoint 12/18/2014
Pfizer (PFE) Reports Top-Line Results From A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As A Treatment For Patients With Postherpetic Neuralgia 12/18/2014
TetraPhase Pharmaceuticals (TTPH) Announces Positive Top-Line Results From Phase 3 IGNITE 1 Clinical Trial Of Eravacycline In Complicated Intra-Abdominal Infections 12/18/2014
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation 12/18/2014
LFB S.A. Announces Achievement Of Patient Enrollment Target For Persept 1 Program For The Evaluation Of Recombinant Factor Seven Efficacy By Prospective Clinical Trials 12/18/2014
Extab Corporation Announces Positive Data From Phase 3 Clinical Study Of Cytisine As A Smoking Cessation Aid Published In The New England Journal Of Medicine 12/18/2014
Hutchison Medipharma Starts Phase III Trial Of Cancer Drug 12/18/2014
RedHill Biopharma Ltd. (RDHL) Announces First Patients Enrolled In The Phase 3 Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis 12/17/2014
Sophiris Bio Inc. (SPHS) Tanks As Phase 3 Data Indicates Drug May Not Be Effective 12/16/2014
Celldex Therapeutics, Inc. (CLDX) Announces Completion Of Enrollment In Phase 3 Study Of Rindopepimut In Frontline Glioblastoma 12/16/2014
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Enrollment Of 486 Patients, DSMB Recommendations And That The Seamless Phase 3 Trial Of Sapacitabine In AML Will Continue To Final Analysis 12/16/2014
Ultragenyx Pharmaceuticals (RARE) Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 12/15/2014
Sophiris Bio Inc. (SPHS) Reports Administrative Interim Analysis For The "PLUS-1" Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia 12/15/2014
Acorda Therapeutics (ACOR) Announces Initiation Of Phase 3 Clinical Trial For Dalfampridine In Post-Stroke Walking Deficits 12/15/2014
Novartis AG (NVS) Psoriasis Drug Tops Johnson & Johnson (JNJ)'s Stelara In Late-Stage Study 12/12/2014
Ipsen (IPN.PA) Announces That The International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating The Use Of Ovarian Suppression To Adjuvant Treatment With Tamoxifen 12/12/2014
Alnylam Pharmaceuticals (ALNY) Initiates ENDEAVOUR Phase 3 Clinical Trial With Revusiran (ALN-Ttrsc), An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis 12/12/2014
Janssen Research & Development Release: Data From The EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented At San Antonio Breast Cancer Symposium 12/12/2014
Head-To-Head Psoriasis Study Demonstrates Superiority Of Novartis AG (NVS) Cosentyx™ To Stelara® In Clearing Skin 12/12/2014
Nektar Therapeutics (CA) (NKTR) Presents Data On Target-Specific Biomarkers From Circulating Tumor Cell Sub-Study Of Phase 3 BEACON Study Of Etirinotecan Pegol (NKTR-102) In Patients With Advanced Breast Cancer 12/12/2014
BeyondSpring To Start China-U.S. Phase 3 Trial Of Novel Cancer Drug 12/12/2014
EXCLUSIVE: AbbVie (ABBV) VP Says New Cancer Drug Could Treat Other Diseases 12/11/2014



//-->